Loading the session
Loading the session
Loading instrument
$36.91
+1.40%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:43 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
Closed at $36.40 on 4 Nov 2026: 0.7% below the 52-week high of $36.67 (15 Oct 2026) and 93.6% above the low of $18.80 (20 Jan 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
1 month: +47.0% (SPY −1.6%, XLV +13.5%). 3 months: +46.4% (SPY −0.4%, XLV +15.5%). 1 year: +62.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: PCRX, SPY and XLV · as of 4 Nov 2026
4.3M shares were sold short at the 15 Oct 2026 settlement, 10.7% of the 39.9M shares outstanding; covering them would take 1.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 14-session relative strength index closed at 83.1 on 4 Nov 2026, its 20th session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
The 4 Nov 2026 close of $36.40 was 22.4% above its 50-day average ($29.75) and 45.1% above its 200-day average ($25.09). It has closed above the 200-day for 56 sessions, since 18 Aug 2026. The 50-day average crossed above the 200-day on 10 Jun 2026, 102 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
October 8, 2026
+44.40%August 9, 2024
−47.67%July 2, 2024
−20.10%